History and Future of the Multidisciplinary Association for Psychedelic Studies (MAPS)

  title={History and Future of the Multidisciplinary Association for Psychedelic Studies (MAPS)},
  author={Amy Emerson and Linnae Pont{\'e} and Lisa Jerome and Rick Doblin},
  journal={Journal of Psychoactive Drugs},
  pages={27 - 36}
Abstract   This article describes the teenage vision of the founder of the Multidisciplinary Association for Psychedelic Studies (MAPS) that humanity’s future would be aided by the therapeutic and spiritual potential of psychedelic substances. The article traces the trajectory of MAPS from inception in 1986 to its present, noting future goals with respect to research, outreach, and harm reduction. MAPS was created as a non-profit psychedelic pharmaceutical company in response to the 1985… 
Current Perspective on MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder
Empirical support for MDMA-assisted psychotherapy, including the randomized, double-blind, placebo-controlled trails that have been conducted since 2008, seems to support MDMA’s safe and effective use as an adjunct to psychotherapy.
The Role of Psychedelics and Counseling in Mental Health Treatment
The purpose of this manuscript is to share the latest psychedelic therapy research and to discuss how mental health counselors can contribute to this reemerging therapeutic trend.
Inclusion of people of color in psychedelic-assisted psychotherapy: a review of the literature
Inclusion of minorities in futures studies and improved recruitment strategies are necessary to better understand the efficacy of psychedelic-assisted psychotherapy in people of color and provide all with equal opportunities for involvement in this potentially promising treatment paradigm.
Developing Guidelines and Competencies for the Training of Psychedelic Therapists
Research since the 1950s has shown that psychedelic-assisted psychotherapy has had significant positive effects in reductions of specific clinical symptoms and increases in quality of life as
The psychedelic renaissance and the limitations of a White-dominant medical framework: A call for indigenous and ethnic minority inclusion
In recent years, the study of psychedelic science has resurfaced as scientists and therapists are again exploring its potential to treat an array of psychiatric conditions, such as depression,
The History of Psychedelics in Medicine
Psychedelics have been used for hundreds if not thousands of years by humans. Medical research began in earnest in theWest in the late nineteenth century with the discovery of mescaline. From there
Examination of the Phenomenology of the Ibogaine Treatment Experience: Role of Altered States of Consciousness and Psychedelic Experiences
Results indicated a positive correlation between the various dimensions of the ASCs and the outcome (ability to make changes in one’s life, cravings, and how changed the person was as a result of ibogaine treatment).
Culturally informed research design issues in a study for MDMA-assisted psychotherapy for posttraumatic stress disorder
Recent research suggests that psychedelic drugs can be powerful agents of change when utilized in conjunction with psychotherapy. Methylenedioxymethamphetamine (MDMA)-assisted psychotherapy has been
The early use of MDMA (‘Ecstasy’) in psychotherapy (1977–1985)
3,4-Methylenedioxymethamphetamine (MDMA), also known as ecstasy, was first synthesized in 1912 but first reached widespread popularity as a legal alternative after the much sought-after recreational


A Clinical Plan for MDMA (Ecstasy) in the Treatment of Posttraumatic Stress Disorder (PTSD): Partnering with the FDA
  • R. Doblin
  • Psychology
    Journal of psychoactive drugs
  • 2002
Abstract The FDA and the Spanish Ministry of Health have concluded that the risk/benefit ratio is favorable under certain circumstances for clinical studies investigating MDMA-assisted psychotherapy.
A method of conducting therapeutic sessions with MDMA.
The therapists' belief was that MDMA inhibited the fear response to a perceived emotional threat, allowing the client to place the emotional sequelae of past experiences into a more realistic perspective in their current emotional lives and relationships.
MDMA-Assisted Psychotherapy Using Low Doses in a Small Sample of Women with Chronic Posttraumatic Stress Disorder
It was found that low doses of MDMA were both psychologically and physiologically safe for all the subjects and future studies in larger samples and using larger doses are needed in order to further clarify the safety and efficacy of MDMA in the clinical setting in subjects with PTSD.
Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial.
The data suggest that sertraline is a safe, well-tolerated, and effective treatment for PTSD.
The safety and efficacy of ±3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study
MDMA-assisted psychotherapy can be administered to posttraumatic stress disorder patients without evidence of harm, and it may be useful in patients refractory to other treatments.
A randomized, controlled pilot study of MDMA (±3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD)
This randomized, double-blind, active-placebo controlled trial found that MDMA-assisted psychotherapy can be safely administered in a clinical setting and did not see statistically significant reductions in CAPS scores, although there was clinically and statistically significant self-reported PDS improvement.
Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study
It was promising that the majority of these subjects with previously severe PTSD who were unresponsive to existing treatments had symptomatic relief provided by MDMA-assisted psychotherapy that persisted over time, with no subjects reporting harm from participation in the study.
The harmful health effects of recreational ecstasy: a systematic review of observational evidence.
A broad range of relatively low-quality literature suggests that recreational use of ecstasy is associated with significant deficits in neurocognitive function (particularly immediate and delayed verbal memory) and increased psychopathological symptoms.
Human pharmacology of 3,4-methylenedioxymethamphetamine ("ecstasy"): psychomotor performance and subjective effects.
The short-term administration of MDMA produced marked euphoria, a slight impairment in the performance of psychomotor tasks, and mild changes in body perceptions without hallucinations, which support the abuse liability of MDMA.